Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG

Deutsche Bank AG reduced its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 87.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,300 shares of the company's stock after selling 208,090 shares during the period. Deutsche Bank AG owned approximately 0.05% of Pyxis Oncology worth $47,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ameriprise Financial Inc. purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $35,000. Caption Management LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter worth $35,000. Commonwealth Equity Services LLC grew its stake in shares of Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares in the last quarter. Bank of America Corp DE increased its holdings in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after buying an additional 9,062 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Pyxis Oncology in the fourth quarter valued at $95,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PYXS has been the subject of several analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a research note on Monday, May 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Stock Performance

NASDAQ PYXS traded up $0.11 during trading hours on Friday, hitting $1.35. The company had a trading volume of 620,780 shares, compared to its average volume of 742,563. The business has a 50 day moving average of $1.09 and a 200-day moving average of $1.37. The company has a market cap of $83.63 million, a PE ratio of -1.31 and a beta of 1.18. Pyxis Oncology, Inc. has a 1-year low of $0.83 and a 1-year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06). Sell-side analysts expect that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.